Wedbush raised the firm's price target on Shattuck Labs to $8 from $4 and keeps an Outperform rating on the shares. The firm notes the company reported earnings, confirmed Crohn's disease as its lead indication, and reiterated guidance for SL-325 results in Q2 2026. Wedbush looks for low ADA rates in the healthy volunteer data as initial proof of differentiation from TL1A directed competitors in addition to other markers like receptor occupancy as mechanistic evidence supporting development.
